VIDEO: Miebo improves dry eye signs, symptoms with ‘unprecedented’ safety
In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating Miebo for the treatment of dry eye disease.
Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) demonstrated statistically significant improvements in both signs and symptoms in all patients analyzed. Sheppard also explained why the safety profile of Miebo is “unprecedented.”
“This data tells us that [perfluorohexyloctane] is a versatile, vehicle-only medication. It has a small drop size of 11 µL, it is well tolerated, it is water free and therefore preservative free, and patients have been responding magnificently since launch in my practice,” he said.
Collapse
Sheppard JD, et al. Perfluorohexyloctane ophthalmic solution for dry eye disease: Efficacy among various participant subgroups in pivotal clinical trials. Presented at: American Society of Cataract and Refractive Surgery meeting; April 5-8, 2024; Boston.
Read more about